US Patent

US11357753 — Rescue treatment of post operative nausea and vomiting

Method of Use · Assigned to Acacia Pharma Ltd · Expires 2038-02-09 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of amisulpride as a rescue treatment for postoperative nausea and/or vomiting in patients who have already received a prophylaxis drug.

USPTO Abstract

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

Drugs covered by this patent

Barhemsys (AMISULPRIDE) · Acacia

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2754`	—	Barhemsys
`U-2754`	—	Barhemsys

Patent Metadata

Patent number: US11357753
Jurisdiction: US
Classification: Method of Use
Expires: 2038-02-09
Drug substance claim: No
Drug product claim: No
Assignee: Acacia Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.